DE60228842D1 - Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels - Google Patents

Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels

Info

Publication number
DE60228842D1
DE60228842D1 DE60228842T DE60228842T DE60228842D1 DE 60228842 D1 DE60228842 D1 DE 60228842D1 DE 60228842 T DE60228842 T DE 60228842T DE 60228842 T DE60228842 T DE 60228842T DE 60228842 D1 DE60228842 D1 DE 60228842D1
Authority
DE
Germany
Prior art keywords
antibody
polyplex
therapeutic
antibody fragment
diagnostic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228842T
Other languages
English (en)
Inventor
Esther H Chang
Kathleen F Pirollo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Application granted granted Critical
Publication of DE60228842D1 publication Critical patent/DE60228842D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60228842T 2001-04-02 2002-04-02 Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels Expired - Lifetime DE60228842D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28013401P 2001-04-02 2001-04-02
PCT/US2002/010160 WO2002078608A2 (en) 2001-04-02 2002-04-02 A simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent

Publications (1)

Publication Number Publication Date
DE60228842D1 true DE60228842D1 (de) 2008-10-23

Family

ID=23071820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228842T Expired - Lifetime DE60228842D1 (de) 2001-04-02 2002-04-02 Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels

Country Status (7)

Country Link
EP (1) EP1408996B1 (de)
AT (1) ATE407684T1 (de)
AU (1) AU2002307035A1 (de)
CA (1) CA2442533C (de)
DE (1) DE60228842D1 (de)
ES (1) ES2312608T3 (de)
WO (1) WO2002078608A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617514B2 (en) * 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
JP2009532361A (ja) * 2006-03-30 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉｇｅを標的としたｄｎａワクチン接種
US20070292497A1 (en) * 2006-05-04 2007-12-20 Martin Francis J Method for treating micrometastatic tumors
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CN113384712A (zh) * 2021-06-11 2021-09-14 潍坊医学院 一种基于同时杀伤肿瘤细胞和CAFs的共载脂质体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642980B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
WO1995035301A1 (en) * 1994-06-22 1995-12-28 Megabios Corporation Cationic amphiphiles
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
EP2258726A1 (de) * 1995-06-14 2010-12-08 The Regents of the University of California Menschliche Antikörper mit hoher Affinität gegen c-erbB-2
PT956001E (pt) * 1996-11-12 2012-12-06 Univ California Preparação de formulações estáveis de complexos do tipo lípido-ácido nucleico para uma entrega eficiente in vivo
WO1999059643A2 (en) * 1998-05-20 1999-11-25 Sdg, Inc. Liposomal delivery complex
CA2362550C (en) * 1999-02-22 2010-05-11 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery

Also Published As

Publication number Publication date
CA2442533A1 (en) 2002-10-10
EP1408996A4 (de) 2006-03-22
EP1408996B1 (de) 2008-09-10
WO2002078608A3 (en) 2004-02-26
EP1408996A2 (de) 2004-04-21
CA2442533C (en) 2014-02-04
WO2002078608A8 (en) 2004-06-03
ES2312608T3 (es) 2009-03-01
ATE407684T1 (de) 2008-09-15
AU2002307035A1 (en) 2002-10-15
WO2002078608A2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
FI960268A0 (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
ATE261337T1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikro- und nanopartikeln mittels eines mikromischers
ATE555133T1 (de) Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE50004742D1 (de) Verfahren zur herstellung von polyetherpolyolen
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
DE68927438D1 (de) Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres
DE502004011239D1 (de) Verfahren zur dehydratisierung substituierter 4-dimethylamino-2-aryl-butan-2-ol-verbindungen und verfahren zur herstellung substituierter dimethyl-(3-katalyse
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
ATE278390T1 (de) Verfahren zur herstellung von arzneistoffpartikeln
ATE402211T1 (de) Verfahren zur herstellung von farblosen, lagerstabilen biuretgruppenhaltigen polyisocyanaten
BR9810243A (pt) Aparelho e processo para fabricação de massa de queijo filata de baixo e reduzido teor de gordura, massa de queijo filata de baixo e reduzido teor de gordura, e, uso da mesma.
NO994822D0 (no) Immunotolerant protrombinkomplekspreparat
DE60228842D1 (de) Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels
ATE372336T1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
DK1699480T3 (da) Allogent terapeutisk tumormiddel
DE59800058D1 (de) Karosseriehohlträger, sowie Verfahren zur dessen Herstellung mittels Innenhochdruck
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
ATE416155T1 (de) Verfahren zur herstellung von bis-ä(3- dimethylamino)propylüamin (bisdmapa)
DE60308066D1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe
DE60114362D1 (de) Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition